TMPRSS6

Matriptase-2; Transmembrane protease serine 6

TMPRSS6 (Matriptase-2) is a serine protease highly expressed in the liver. TMPRSS6 functions as a negative regulator of the expression of the systemic iron-regulatory hormone hepcidin.

TMPRSS6 Inhibitors (7)

TMPRSS6 Related Products (7):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-177662

Sapablursen	Inhibitor
Sapablursen, an antisense oligonucleotide, is designed to reduce the production of TMPRSS6 resulting in increased expression of hepcidin, which is the key regulator of iron homeostasis. Sapablursen can be used in the research of blood diseases such as pol

HY-147278C

Manusiran sodium scrambled negative control	Inhibitor
Manusiran sodium scrambled negative control is the sequence scrambled negative control of Manusiran sodium.

HY-177663A

SARSi-4 sodium scrambled negative control	Inhibitor
SARSi-4 sodium scrambled negative control is the sequence scrambled negative control of SARSi-4 sodium.

HY-177662A

Sapablursen sodium	Inhibitor
Sapablursen sodium, an antisense oligonucleotide, is designed to reduce the production of TMPRSS6 resulting in increased expression of hepcidin, which is the key regulator of iron homeostasis. Sapablursen sodium can be used in the research of blood diseas

HY-147278A

Manusiran sodium	Inhibitor
Manusiran (SLN124) sodium, a GalNAc conjugated 19-mer siRNA targeting TMPRSS6 (transmembrane protease serine 6), reduces plasma iron and increases hepcidin levels^[1][2].

HY-147278

Manusiran	Inhibitor
Manusiran (Divesiran) is a GalNac-siRNA targeting liver and transmembrane serine protease 6 (Serine protease 6). Manusiran increases hepatic Hepcidin synthesis and plasma levels by silencing TMPRSS6, a negative regulator of hepcidin production, and limits the availability of iron required for erythropoiesis. Combined use of Manusiran with Deferiprone (HY-B0568) reduces ineffective erythropoiesis and hepatic iron overload in a mouse model of β-thalassemia. Manusiran can be used for research on polycythemia vera, type 1 hereditary hemochromatosis, and β-thalassemia.

HY-180217

WGU55	Inhibitor
WGU55 is a selective and potent reversible type II transmembrane serine protease TMPRSS6 inhibitor with a K_i of 12.15 nM. WGU55 inhibits TMPRSS6 activity with an IC₅₀ of 138 nMin KEK293 cells. WGU55 has a K_i of 3510 nM (SI = 289) against the homologous protease matriptase and a K_i of 5.2 μM against the coagulation key protease Factor Xa. WGU55 can be used for the research of iron overload related diseases, such as hereditary hemochromatosis.

Name
Email *

	Sorry, but the email address you supplied was invalid.